- About Us
- Media Release
- Our Clients
- Media Mentions
- Subscription Model
- Contact Us
According to a new report Global Autoinjectors Market, published by KBV research, The Global Autoinjectors Market size is expected to reach $5.3 billion by 2026, rising at a market growth of 17.6% CAGR during the forecast period.
In 2019, Anaphylaxis segment held the largest market share of the autoinjectors market, owing to the growing incidence of rheumatoid arthritis also drives the demand for autoinjectors worldwide. The Rheumatoid Arthritis market would exhibit a CAGR of 16.4% during (2020 - 2026).
On the basis of end-user, the autoinjectors market is divided into hospitals & clinics and home care settings. The home care settings segment had the largest market share in the year 2019 and can largely be credited to the swift growth in the geriatric population in the world and the increasing requirement for cost-effective administration of drugs. The Hospitals & Clinics market is expected to witness highest CAGR of 18.3% during the forecast period.
North America led the market in the year 2019 and is anticipated to maintain its dominance throughout the foreseeable period. This can be accredited to technological advancements in medical devices, progressive healthcare infrastructure, and higher demand for quality products. The Asia Pacific market is estimated to grow at a CAGR of 19.1% during (2020 - 2026). Additionally, The Europe market would showcase a CAGR of 17.1% during the forecast period.
Structural Insights: https://www.kbvresearch.com/autoinjectors-market/
The market research report has exhaustive quantitative insights providing a clear picture of the market potential in various segments across the globe with country wise analysis in each discussed region. The key impacting factors of the market have been discussed in the report with the elaborated company profiles of Eli Lilly and Company, GlaxoSmithKline PLC (GSK), Merck Group, Sanofi S.A., Becton, Dickinson and Company, Teva Pharmaceuticals Industries Ltd., Amgen, Inc., Ypsomed AG, AbbVie, Inc. and Biogen, Inc.
By End Use
Unique Offerings from KBV Research